

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Strous et al.

**Serial No.:** To be assigned

**Filed:** September 12, 2000

**For:** CONTROLLING AVAILABILITY OR  
ACTIVITY OF PROTEINS BY USE OF  
PROTEASE INHIBITORS OR RECEPTOR  
FRAGMENTS

**Examiner:** To be assigned

**Group Art Unit:** To be assigned

**Attorney Docket No.:** 4525US

**NOTICE OF EXPRESS MAILING**

Express Mail Mailing Label  
Number: EL700253295US

Date of Deposit with USPS: September 12, 2000

Person making Deposit: Jared Turner



**STATEMENT PER 37 C.F.R. § 1.821(f)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:


I, Kenneth B. Ludwig, registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the substitute SEQUENCE LISTING, as well as the enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF), are included herewith to comply with the requirements of 37 C.F.R. §§ 1.821-1.825, as requested by the Examiner.

2. The enclosed copy of the substitute SEQUENCE LISTING in computer readable form (CRF) is believed to be identical to the paper copy of the substitute SEQUENCE LISTING.

3. The SEQUENCE LISTINGS submitted herewith are believed to contain no "new matter" with regard to the referenced patent application.

Respectfully submitted,



Kenneth B. Ludwig  
Registration No. 42,814  
Attorney for Applicants  
TRASK BRITT  
P. O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: (801) 532-1922

Date: September 12, 2000

N:\2183\4525\Sequence listing statement.wpd